Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06779695
Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)
Sponsor: Korea University Anam Hospital
View on ClinicalTrials.gov
Summary
Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
2000
Start Date
2024-04-21
Completion Date
2031-12-31
Last Updated
2025-01-16
Healthy Volunteers
No
Conditions
Locations (1)
Korea University Anam Hospital
Seoul, South Korea